Abstract

INTRODUCTION

Aging is associated with a progressive loss of muscle mass, quality and strength, which results in a condition known as sarcopenia. In 1989, Rosenberg and Roubenoff [¹] proposed the term sarcopenia, originating from the Greek words sarx (flesh) and penia (loss). Sarcopenia has been defined as "the age-associated loss of skeletal muscle mass, which results in decreased strength and aerobic capacity and thus functional capacity" [²]. Lean muscle mass contributes up to 50% of total body weight in young adults but declines with age to 25% at 80 years old [³]. After 50 years of age, approximately 1% to 2% of muscle mass is expected to be lost per year, and muscle strength decreases at an even greater rate [⁴]. Sarcopenia is characterized by atrophy of type II muscle fiber and reduction in muscle fiber satellite cells with aging [⁵]. Interestingly, young men have twice as much muscle mass as fat mass, whereas this ratio is almost reversed in older men [⁶]. Aging is also related to increased visceral fat mass, which is an important factor in the development of metabolic syndrome, type 2 diabetes and cardiovascular disease. Sarcopenia and visceral obesity may have a synergistic impact on both chronic metabolic disorders and physical disability [⁷].

DEFINITION OF SARCOPENIA

Several different definitions of sarcopenia and sarcopenic obesity have been proposed in previous studies. Baumgartner et al. [⁸] defined sarcopenia as a two or greater standard deviation (SD) reduction in appendicular skeletal muscle (ASM) divided by height squared (ASM/height²) below the normal mean for a young reference group measured using dual X-ray absorptiometry [⁸]. Janssen et al. [⁹] proposed a definition of sarcopenia as skeletal muscle mass index (skeletal muscle mass [kg]/weight [kg]×100) one or two SD below the mean for a younger reference group. Newman et al. [¹⁰] introduced an alternative definition of sarcopenia, using appendicular lean mass adjusted for height and body fat mass (residuals). Recently, the European Working Group on Sarcopenia in Older People developed a practical clinical definition and recommends using the presence of both low muscle mass and low muscle function (strength or performance) for the diagnosis of sarcopenia [¹¹]. Table 1 summarizes the measurement of muscle mass, strength, and function. The International Working Group on Sarcopenia proposed that a diagnosis of sarcopenia is consistent with a gait speed of less than 1 m/sec and an objectively measured low muscle mass (e.g., ASM mass relative to height² that is ≤7.23 kg/m² in men and ≤5.67 kg/m² in women) [²].

Table 1

Measurements of Muscle Mass, Strength, and Function

Open in a separate window

^aRecommended for clinical practice.

MECHANISMS OF SARCOPENIA

INFLUENCE OF SARCOPENIA AND SARCOPENIC OBESITY

Previous studies have reported that sarcopenia is associated with risk of adverse outcomes, such as physical disability, poor quality of life, and death. In an early study by Baumgartner et al. [⁸], sarcopenia was significantly associated with a 3-fold to 4-fold increased risk of physical disability in both men and women [⁸]. They also reported a relationship between sarcopenia and falls in the previous year. After adjustment for other confounding factors, the odds ratio for falls was statistically significant in men at 2.58 (95% confidence interval [CI], 0.60 to 2.67) but not in women at 1.28 (95% CI, 0.60 to 2.67) [⁸]. In the Korean Sarcopenic Obesity Study (KSOS) of 810 subjects (414 patients with type 2 diabetes and 396 control subjects), we found that type 2 diabetes was independently associated with increased risk of sarcopenia [²²]. Furthermore, we observed that sarcopenic obesity was associated with the risk of metabolic syndrome [²³]. Park et al. [²⁴] showed that type 2 diabetes is associated with excessive loss of skeletal muscle, and that older women with type 2 diabetes in the Health ABC cohort are at especially high risk for loss of skeletal muscle mass [²⁴]. Recently, Lim et al. [²⁵] found that sarcopenic obesity, defined by ASM/weight, was more closely associated with metabolic syndrome than either sarcopenia or obesity alone. In a study including 1,396 men and women aged 70 years and older, low arm muscle area was associated with an elevated mortality rate during an 8-year follow-up period (hazard ratio, 1.95; 95% CI, 1.25 to 2.00) [²⁶]. Heitmann et al. [²⁷] reported that lower levels of fat-free mass were associated with an increased risk of mortality among 787 men aged 60 years and older who were followed for 22 years. Recent studies suggest that subjects with less common body-size phenotypes, such as metabolically abnormal but normal weight or metabolically healthy obese, seem to be more prone or more resistant, respectively, to the development of obesity-associated metabolic disorders. We observed that low muscle mass might be a factor associated with different metabolic consequences according to body-size phenotype in the KSOS cohort [²⁸].

CONCLUSIONS

Both sarcopenia and obesity are becoming major threats to aging society. The concept of sarcopenic obesity may help to elucidate the interrelationship between physical disability, metabolic disorders and mortality in the elderly population. More research about sarcopenia and sarcopenic obesity is needed to improve morbidity and mortality as consequences of rapidly aging society.

ACKNOWLEDGMENTS

Footnotes

References